» Authors » A B Kremer

A B Kremer

Explore the profile of A B Kremer including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 12
Citations 167
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Zujewski J, Horak I, Bol C, Woestenborghs R, Bowden C, End D, et al.
J Clin Oncol . 2000 Feb; 18(4):927-41. PMID: 10673536
Purpose: To determine the maximum-tolerated dose, toxicities, and pharmacokinetic profile of the farnesyl protein transferase inhibitor R115777 when administered orally bid for 5 days every 2 weeks. Patients And Methods:...
2.
Scher H, KELLY W, Zhang Z, Ouyang P, Sun M, Schwartz M, et al.
J Natl Cancer Inst . 1999 Feb; 91(3):244-51. PMID: 10037102
Background: With an hypothesis that post-chemotherapy changes in serum prostate-specific antigen (PSA) levels might serve as a surrogate marker for assessing prostate cancer outcome (i.e., survival), we studied the relationship...
3.
Horak I, Kremer A, Magrath I
Baillieres Clin Haematol . 1996 Dec; 9(4):707-26. PMID: 9138614
The NHLs are a group of neoplasms that share a common target tissue, and are characterized by a high degree of biological and clinical heterogeneity. Adult lymphomas with a high...
4.
Seidmon E, Trump D, Kreis W, Hall S, Kurman M, Ouyang S, et al.
Ann Surg Oncol . 1995 Nov; 2(6):550-6. PMID: 8591087
Background: Liarozole binds to the cytochrome P-450-dependent hydroxylating enzymes involved in steroid biosynthesis and retinoic acid catabolism. This phase I study investigated the clinical/endocrine toxicity profile of liarozole and determined...
5.
Fischl M, RESNICK L, Coombs R, Kremer A, Pottage Jr J, Fass R, et al.
J Acquir Immune Defic Syndr (1988) . 1994 Feb; 7(2):139-47. PMID: 7905523
We conducted a double-blind, randomized phase II study to evaluate the safety and activity of combination therapy with N-butyl-deoxynojirimycin (SC-48334) (an alpha-glucosidase I inhibitor) and zidovudine versus zidovudine alone. Patients...
6.
Conant M, Calabrese L, THOMPSON S, Poiesz B, Rasheed S, Hirsch R, et al.
AIDS . 1992 Nov; 6(11):1335-9. PMID: 1361746
Objective: To assess the efficacy and safety of thymopentin in HIV-infected patients who had not yet developed AIDS. Design: Patients were stratified into asymptomatic or symptomatic groups and randomized to...
7.
Goldstein G, Kremer A, Barnes L, Hirsch R
J Pediatr . 1987 Dec; 111(6 Pt 2):1046-50. PMID: 3316579
The monoclonal antibody OKT3 was previously shown to be superior to conventional high-dose steroid therapy for reversal of acute rejection of renal allografts. Furthermore, OKT3 was effective in reversing acute...
8.
Kremer A, Barnes L, Hirsch R, Goldstein G
Transplant Proc . 1987 Apr; 19(2 Suppl 1):54-7. PMID: 3105141
No abstract available.
9.
Hirsch R, Layton P, Barnes L, Kremer A, Goldstein G
Transplant Proc . 1987 Apr; 19(2 Suppl 1):32-6. PMID: 3105138
No abstract available.
10.
Kremer A, Mikita T, Beardsley G
Biochemistry . 1987 Jan; 26(2):391-7. PMID: 3828314
The cytotoxic analogue of thymine, 5-fluorouracil (Uf), is known to be incorporated into DNA in biological systems. This abnormal base has been synthetically incorporated into short DNA oligomers. The ionization...